JBIO

Jade Biosciences Inc

14.69

Oct 23 • 2:10 PM ET -0.22 (-1.51%)

Healthcare Biotechnology USA Small NASD

Oct 21, 7:36 AMJade Biosciences expects EVERGREEN Phase 3 JADE101 IgA nephropathy trial to start in Q4 2026, JUNIPER Phase 2 interim data in Q2 2027

Peers: VERA CLYM TVTX ZBIO DNTH OMER ANAB AUPH VRDN IMVT

| Held by: XBI VTI IWM VXF IWO SCHA VTWO FFSM IWC VHT

Scroll to Statements

Index	RUT
Market Cap	933.93M
Enterprise Value	473.36M
Income	-136.45M
Sales	0.00M
Book/sh	6.92
Cash/sh	7.25
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	55
IPO	Jun 30, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.12
P/C	2.03
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	14.93
Current Ratio	14.93
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-2.61
EPS next Y	-2.92
EPS next Q	-0.73
EPS this Y	7.46%
EPS next Y	0.95%
EPS next 5Y	3.75%
EPS past 3/5Y	61.94% 21.92%
Sales past 3/5Y	- -
EPS Y/Y TTM	91.41%
Sales Y/Y TTM	-
EPS Q/Q	33.03%
Sales Q/Q	-
Earnings	Aug 10 BMO
EPS/Sales Surpr.	-19.42% -

Insider Own	14.30%
Insider Trans	0.00%
Inst Own	102.04%
Inst Trans	47.33%
ROA	-44.03%
ROE	-47.78%
ROIC	-34.78%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	4.24%
SMA50	-15.40%
SMA200	-19.43%
Trades

Shs Outstand	63.56M
Shs Float	54.50M
Short Float	22.24%
Short Ratio	13.48
Short Interest	12.12M
52W High	28.00 -47.55%
52W Low	8.36 75.66%
Volatility	6.73% 6.36%
ATR (14)	0.93
RSI (14)	45.70
Beta	1.67
Rel Volume	0.51
Avg Volume	898.87K
Volume	338,770

Perf Week	9.02%
Perf Month	-0.31%
Perf Quarter	-26.39%
Perf Half Y	-41.21%
Perf YTD	-4.83%
Perf Year	47.89%
Perf 3Y	-63.59%
Perf 5Y	-69.71%
Perf 10Y	-
Recom	1.00
Target Price	49.89
Prev Close	14.91
Price	14.69
Change %	-1.51%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-15-26	Initiated	UBS	Buy	$45
Jan-07-26	Initiated	H.C. Wainwright	Buy	$25
Oct-09-25	Initiated	BTIG Research	Buy	$28
Jul-14-25	Initiated	Jefferies	Buy	$16
Jun-16-25	Upgrade	Guggenheim	Neutral → Buy	$14
May-07-25	Initiated	Wedbush	Outperform	$17
May-05-25	Initiated	Stifel	Buy	$19
May-02-25	Initiated	TD Cowen	Buy	$10
Jun-18-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$35 → $2
Jun-18-24	Downgrade	TD Cowen	Buy → Hold
Jun-18-24	Downgrade	Evercore ISI	Outperform → In-line	$27 → $2
Jun-17-24	Downgrade	Wedbush	Outperform → Neutral	$41 → $3
Jun-17-24	Downgrade	Guggenheim	Buy → Neutral
Jun-17-24	Downgrade	BTIG Research	Buy → Neutral
Mar-25-24	Resumed	Jefferies	Buy	$21 → $65
Dec-08-23	Initiated	Wells Fargo	Equal Weight	$35
Mar-01-23	Initiated	Guggenheim	Buy	$36
Dec-06-22	Upgrade	BTIG Research	Neutral → Buy	$27
Sep-19-22	Resumed	Wedbush	Outperform	$27
Aug-16-22	Downgrade	BTIG Research	Buy → Neutral

Show Previous Ratings

Oct-21-26 07:00AM	Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026 (GlobeNewswire)
Sep-30-26 07:00AM	Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-ß Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026 (GlobeNewswire)
Sep-01-26 07:00AM	Jade Biosciences to Participate in Upcoming Conferences (GlobeNewswire)
Aug-10-26 07:00AM	Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-23-26 11:56AM	Nuvectis' NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor (FinanceWire)
07:35AM	Loading…
Jul-09-26 07:35AM	The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush (FinanceWire)
Jun-26-26 07:00AM	Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors (GlobeNewswire)
Jun-05-26 04:01PM	Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -11.57%
Jun-03-26 10:58PM	Jade Biosciences Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:01PM	Jade Biosciences Announces Proposed Underwritten Public Offering (GlobeNewswire)
Jun-01-26 07:00AM	Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy (GlobeNewswire) -11.64%
May-29-26 04:05PM	Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy (GlobeNewswire)
May-26-26 04:05PM	Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody (GlobeNewswire)
07:00AM	Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy (GlobeNewswire)
May-07-26 04:05PM	Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) +6.56%
07:00AM	Loading…
Apr-23-26 07:00AM	Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-22-26 07:00AM	Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer (GlobeNewswire) +10.30%
Mar-06-26 07:00AM	Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-28-26 11:41AM	Jade Biosciences Touts Best-in-Class Autoimmune Antibodies, JADE101 Phase 1 Readout Nears (MarketBeat)
Feb-11-26 07:00AM	Jade Biosciences to Participate in Upcoming Conferences (GlobeNewswire)
Jan-19-26 08:01AM	H.C. Wainwright Initiates Jade Biosciences (JBIO) at Buy With $25 PT as JADE101 Eyes $926M Peak Revenue (Insider Monkey)
Jan-05-26 07:00AM	Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -7.34%
Dec-15-25 07:00AM	Jade Biosciences Announces $45 Million Private Placement (GlobeNewswire)
Dec-10-25 02:15PM	Jade Biosciences (JBIO): Analyst Lauds Entry into Market (Insider Monkey)
Dec-04-25 09:55AM	Does Jade Biosciences, Inc. (JBIO) Have the Potential to Rally 65% as Wall Street Analysts Expect? (Zacks)
Nov-18-25 12:00PM	What Makes Jade Biosciences, Inc. (JBIO) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Predict a 52.5% Upside in Jade Biosciences, Inc. (JBIO): Here's What You Should Know (Zacks)
Nov-13-25 04:05PM	Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +10.54%
Nov-08-25 11:00AM	Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025 (GlobeNewswire)
Nov-03-25 07:00AM	Jade Biosciences to Participate in Upcoming Conferences (GlobeNewswire)
04:05PM	Loading…
Oct-17-25 04:05PM	Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025 (GlobeNewswire) +6.72%
Oct-07-25 07:05AM	Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases (GlobeNewswire)
07:00AM	Jade Biosciences Announces $135 Million Private Placement (GlobeNewswire)
Sep-02-25 07:00AM	Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy (GlobeNewswire)
Aug-25-25 07:00AM	Jade Biosciences to Participate in Upcoming Conferences (GlobeNewswire)
Aug-13-25 04:05PM	Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -7.64%
Jul-10-25 04:00AM	The early winner in the 'Dexit' war for corporate relocations: Nevada (Yahoo Finance)
Jul-08-25 07:00AM	Jade Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Jul-01-25 07:00AM	Jade Biosciences Appoints Brad Dahms as Chief Financial Officer (GlobeNewswire) +8.56%
Jun-24-25 07:30AM	2 Small-Cap Stocks Under $10 to Buy With Big Potential (Barchart) +6.18%
Jun-09-25 07:00AM	Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy (GlobeNewswire) +7.23%
Jun-02-25 07:00AM	Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress (GlobeNewswire)
May-14-25 04:05PM	Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -12.31%
May-13-25 07:00AM	Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
Apr-26-25 11:00AM	Microsoft, Apple Set To Report Earnings As Markets Watch Out For Core PCE Price Index (Seeking Alpha)
Apr-21-25 08:00AM	Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals (PR Newswire)
Apr-09-25 04:05PM	Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences (PR Newswire)
Apr-07-25 08:30AM	Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences (PR Newswire)
Oct-31-24 08:18AM	Jade, another biotech spinout of Paragon, to merge with Aerovate (BioPharma Dive) +11.87%
07:00AM	Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement (GlobeNewswire)
Jul-08-24 08:00AM	Ligand to buy Apeiron; Roche reports another TIGIT setback (BioPharma Dive) +8.07%
08:00AM	Aerovate Therapeutics to Explore Strategic Alternatives (GlobeNewswire)
Jul-02-24 01:13PM	Aerovate slashes workforce after failed Phase IIb trial (Clinical Trials Arena)
Jun-27-24 07:00AM	The 3 Hottest Stock Downgrades From Last Week (InvestorPlace) +15.97%
Jun-18-24 09:21AM	Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals (Zacks) -14.55%
Jun-17-24 04:11PM	Aerovate Therapeutics Stock Dropped Over 90%. Heres Why. (Barrons.com) -93.30%
04:04PM	Why 93% Of Aerovate Therapeutics' Value Just Went Up In Smoke (Investor's Business Daily)
08:32AM	Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension (GlobeNewswire)
May-21-24 04:15PM	Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference (GlobeNewswire) -9.04%
May-13-24 09:54PM	AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
04:30PM	Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights (GlobeNewswire)
Apr-04-24 01:31AM	Aerovate Therapeutics Inc CEO Timothy Noyes Sells 10,000 Shares (GuruFocus.com)
Mar-27-24 09:20AM	Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference (GlobeNewswire) +11.11%
Mar-26-24 09:01PM	Aerovate Therapeutics Inc (AVTE) Reports Increased R&D Expenses and Net Loss in 2023 (GuruFocus.com)
Mar-25-24 09:53PM	AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
04:10PM	Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights (GlobeNewswire)
Mar-21-24 02:32AM	Chief Medical Officer Hunter Gillies Sells 7,000 Shares of Aerovate Therapeutics Inc (AVTE) (GuruFocus.com)
02:32AM	Insider Sell: Aerovate Therapeutics Inc's (AVTE) Chief Technical Officer Marinus Verwijs Sells ... (GuruFocus.com)
Mar-06-24 08:00AM	Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair (GlobeNewswire)
Dec-16-23 11:01AM	Insider Sell Alert: Chief Medical Officer Hunter Gillies Sells 12,000 Shares of Aerovate ... (GuruFocus.com)
Nov-20-23 04:45PM	Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension (GlobeNewswire)
Nov-13-23 11:09AM	Aerovate Therapeutics Inc Reports Increased R&D Expenses and Net Loss in Q3 (GuruFocus.com) +8.45%
08:00AM	Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights (GlobeNewswire)
Oct-30-23 09:32AM	12 Best Micro Cap Stocks To Invest In (Insider Monkey)
Sep-19-23 05:07AM	Down More Than 50%: 2 Strong Buy Stocks That Are Too Cheap to Ignore (TipRanks)
Aug-28-23 08:20AM	TENX: Second Quarter Results (Zacks)
Aug-14-23 08:00AM	Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights (GlobeNewswire)
Jul-22-23 09:29AM	Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jul-11-23 05:00PM	Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors (GlobeNewswire)
Jun-23-23 06:24AM	TENX: Notice of Allowance Increases Confidence (Zacks Small Cap Research)
Jun-01-23 08:00AM	Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-23 01:15PM	Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference (GlobeNewswire)
May-15-23 04:05PM	Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights (GlobeNewswire) -7.45%
Mar-29-23 04:50PM	Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights (GlobeNewswire)
Mar-02-23 08:00AM	Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-12-23 08:07AM	We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth (Simply Wall St.)
Jan-23-23 08:00AM	Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors (GlobeNewswire)
Dec-31-22 08:22AM	Calculating The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) (Simply Wall St.)
Dec-28-22 10:15PM	12 Best Performing Biotech Stocks in 2022 (Insider Monkey)
Dec-06-22 01:19PM	Analyst Turns Bullish On Aerovate As Competitor Data Reinforce Lead Program Thesis (Benzinga)
Nov-17-22 07:45AM	Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research (GlobeNewswire)
Nov-14-22 07:45AM	Aerovate Therapeutics Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-18-22 08:00AM	Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022 (GlobeNewswire) +5.28%
Sep-05-22 07:17AM	Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Aug-15-22 07:50AM	Aerovate Therapeutics Announces Second Quarter 2022 Financial Results (GlobeNewswire)
Jun-02-22 08:00AM	Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-16-22 05:15PM	Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH) (GlobeNewswire) -11.25% +5.60%
08:00AM	Aerovate Therapeutics Announces First Quarter 2022 Financial Results (GlobeNewswire)
Mar-30-22 04:45PM	Aerovate Therapeutics Announces Full-Year 2021 Financial Results (GlobeNewswire) +5.72%
Mar-29-22 11:42AM	We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth (Simply Wall St.) +11.35%

Show Previous News

Jade Biosciences, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.

PresidentMr. Tom Frohlich

CFO & TreasurerMr. Bradford D. Dahms Ph.D.

D.V.M.Dr. Andrew James King BVMS

Chief Legal Officer & Corporate SecretaryMs. Elizabeth Balta J.D.

Senior Vice President of PeopleMs. Lori Stewart

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JBIO

Jade Biosciences Inc

Upgrade your Finviz experience